YMTX vs. LUMO, ONTX, VINC, SYBX, MEIP, HUGE, BIVI, FLGC, RNXT, and CPIX
Should you be buying Yumanity Therapeutics stock or one of its competitors? The main competitors of Yumanity Therapeutics include Lumos Pharma (LUMO), Onconova Therapeutics (ONTX), Vincerx Pharma (VINC), Synlogic (SYBX), MEI Pharma (MEIP), FSD Pharma (HUGE), BioVie (BIVI), Flora Growth (FLGC), RenovoRx (RNXT), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceutical preparations" industry.
Lumos Pharma (NASDAQ:LUMO) and Yumanity Therapeutics (NASDAQ:YMTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.
Yumanity Therapeutics has a net margin of -660.61% compared to Yumanity Therapeutics' net margin of -1,659.39%. Yumanity Therapeutics' return on equity of -85.63% beat Lumos Pharma's return on equity.
Lumos Pharma currently has a consensus price target of $18.00, suggesting a potential upside of 538.30%. Given Yumanity Therapeutics' higher possible upside, analysts plainly believe Lumos Pharma is more favorable than Yumanity Therapeutics.
In the previous week, Lumos Pharma had 1 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 2 mentions for Lumos Pharma and 1 mentions for Yumanity Therapeutics. Yumanity Therapeutics' average media sentiment score of 0.00 equaled Lumos Pharma'saverage media sentiment score.
Lumos Pharma received 20 more outperform votes than Yumanity Therapeutics when rated by MarketBeat users. Likewise, 77.27% of users gave Lumos Pharma an outperform vote while only 70.00% of users gave Yumanity Therapeutics an outperform vote.
Lumos Pharma has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Yumanity Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.
Lumos Pharma has higher earnings, but lower revenue than Yumanity Therapeutics. Lumos Pharma is trading at a lower price-to-earnings ratio than Yumanity Therapeutics, indicating that it is currently the more affordable of the two stocks.
34.0% of Lumos Pharma shares are owned by institutional investors. Comparatively, 25.1% of Yumanity Therapeutics shares are owned by institutional investors. 25.4% of Lumos Pharma shares are owned by insiders. Comparatively, 12.5% of Yumanity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Lumos Pharma beats Yumanity Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Yumanity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Yumanity Therapeutics Competitors List
Related Companies and Tools
